Date: 2013-03-11
Type of information:
Compound: portfolio of sangamides, cyclophilin inhibitors
Company: Neurovive Pharmaceutical (Sweden) Biotica (UK)
Therapeutic area: Cardiovascular diseases - CNS diseases
Type agreement: acquisition
Action mechanism:
Disease:
Details: NeuroVive, a mitochondrial medicine company, has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from the UK biotech company Biotica Ltd. In January 2013 Biotica was placed into administration.
The acquisition of these assets will allow NeuroVive to broaden and deepen its pipeline of novel mitochondrial medicines. The portfolio of novel cyclophilin inhibitors is from a new class of molecules called Sangamides based on a novel chemistry platform of polyketides around which NeuroVive has also acquired the intellectual property rights. These novel cyclophilin inhibitors are expected to form the basis of the next-generation of NeuroVive products for a broad range of diseases including cardio- and neuroprotection.
NeuroVive is presently developing a portfolio of products to treat important acute cardiovascular and neurological conditions through mitochondrial protection. Its leading products, CicloMulsion® and NeuroSTAT®, are special formulations of the cyclophilin inhibitor cyclosporine for two prioritized indications, the prevention of reperfusion injury following stenting after myocardial infarction and traumatic brain injury respectively. CicloMulsion® is currently in a 1,000 patient Phase III trial assessing its ability to reduce overall mortality and the number of patients developing heart failure following stenting in patients with myocardial infarction. This trial is expected to complete recruitment by the end of 2013.
Financial terms: No financial details of the acquisition are being disclosed.
Latest news:
